Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Narrative Review of Brivaracetam: Preclinical Profile and Clinical Benefits in the Treatment of Patients with Epilepsy

Open access
Klein, Pavel, Bourikas, Dimitrios · 2024 · Advances in Therapy

Abstract

One third of patients with epilepsy will continue to have uncontrolled seizures despite treatment with antiseizure medications (ASMs). There is therefore a need to develop novel ASMs. Brivaracetam (BRV) is an ASM that was developed in a major drug discovery program aimed at identifying selective, high-affinity synaptic vesicle protein 2A (SV2A) ligands, the target molecule of levetiracetam. BRV binds to SV2A with 15- to 30-fold higher affinity and greater selectivity than levetiracetam. BRV has broad-spectrum antiseizure activity in animal models of epilepsy, a favorable pharmacokinetic profile, few clinically relevant drug-drug interactions, and rapid brain penetration. BRV is available in oral and intravenous formulations and can be initiated at target dose without titration. Efficacy and safety of adjunctive BRV (50–200 mg/day) treatment of focal-onset seizures was demonstrated in three pivotal phase III trials (NCT00490035/NCT00464269/NCT01261325), including in patients who had previously failed levetiracetam. Efficacy and safety of adjunctive BRV were also demonstrated in adult Asian patients with focal-onset seizures (NCT03083665). In several open-label trials (NCT00150800/NCT00175916/NCT01339559), long-term safety and tolerability of adjunctive BRV was established, with efficacy maintained for up to 14 years, with high retention rates. Evidence from daily clinical practice highlights BRV effectiveness and tolerability in specific epilepsy patient populations with high unmet needs: the elderly (≥ 65 years of age), children (< 16 years of age), patients with cognitive impairment, patients with psychiatric comorbid conditions, and patients with acquired epilepsy of specific etiologies (post-stroke epilepsy/brain tumor related epilepsy/traumatic brain injury-related epilepsy). Here, we review the preclinical profile and clinical benefits of BRV from pivotal trials and recently published evidence from daily clinical practice. One in three people with epilepsy continue to have seizures despite treatment. Brivaracetam is a medicine used to treat seizures in people with epilepsy. It binds to a protein in the brain (synaptic vesicle protein 2A) and is effective in many different animal models of epilepsy. Brivaracetam enters the brain quickly. It has few interactions with other medicines, which is important because people with epilepsy may be taking additional medicines for epilepsy or other conditions. Brivaracetam is available as tablets, oral solution, and solution for intravenous injection, can be started at the recommended target dose, and is easy to use. In three phase III trials, people with uncontrolled focal-onset seizures taking brivaracetam 50–200 mg each day had fewer seizures than people taking a placebo. Brivaracetam was tolerated well. It also worked well in many people who had previously not responded to antiseizure medications. The efficacy of brivaracetam treatment is maintained for up to 14 years. Brivaracetam treatment reduces seizures in the elderly (≥ 65 years old), in children (< 16 years old), in people with cognitive or learning disabilities, in people with additional psychiatric conditions, and in people with different causes of epilepsy (post-stroke epilepsy, brain-tumor related epilepsy, and traumatic brain injury-related epilepsy). Here, we review brivaracetam characteristics and the results when people with epilepsy received brivaracetam in key clinical trials and real-world studies in daily clinical practice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12325-024-02876-z

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Mechanism of action of clinically approved ASMs. Drugs marked with asterisks indicate that these compounds act by multiple mechanisms (not all mechanisms shown here). AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, ASM antiseizure medication, GABA gamma-aminobutyric acid, GABA-T GABA aminotransferase, GAT GABA transporter, KCNQ a family of voltage-gated potassium channels (also known as the Kv7 family), NMDA N-methyl-D-aspartate, SV2A synaptic vesicle protein 2A. Reproduced with small modifications from Fig. 1 of Löscher et al. [69], licensed under CC BY-NC 4.0
Fig. 1 Mechanism of action of clinically approved ASMs. Drugs marked with asterisks indicate that these compounds act by multiple mechanisms (not all mechanisms shown here). AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, ASM antiseizure medication, GABA gamma-aminobutyric acid, GABA-T GABA aminotransferase, GAT GABA transporter, KCNQ a family of voltage-gated potassium channels (also known as the Kv7 family), NMDA N-methyl-D-aspartate, SV2A synaptic vesicle protein 2A. Reproduced with small modifications from Fig. 1 of Löscher et al. [69], licensed under CC BY-NC 4.0CC BY-NC · PubMed Central
Fig. 2 Overview of drug discovery efforts at UCB based on modulation of the pyrrolidone-acetamide scaffold (a), properties of BRV and LEV (b), and proposed mechanism of action of BRV and LEV (C). AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, BRV brivaracetam, GABA gamma-aminobutyric acid, GAD 65 glutamate decarboxylase 65, HVA high-voltage-activated, IC50 inhibitory half maximal concentration, Ki equilibrium constant, LEV levetiracetam, MES maximal electroshock seizure test, PTZ subcutaneous pentylenetetrazole seizure test, SV2A synaptic vesicle protein 2A. a Reproduced from Fig. 1 of Klitgaard et al. [7], licensed under CC BY-NC-ND 4.0. b Reproduced from Table 31.2 of D’Souza et al. [70], with permission from John Wiley & Sons, Ltd. Panel C: Reproduced with small modifications from Fig. 1 of Feyissa [71], licensed under CC BY-NC 4.0
Fig. 2 Overview of drug discovery efforts at UCB based on modulation of the pyrrolidone-acetamide scaffold (a), properties of BRV and LEV (b), and proposed mechanism of action of BRV and LEV (C). AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, BRV brivaracetam, GABA gamma-aminobutyric acid, GAD 65 glutamate decarboxylase 65, HVA high-voltage-activated, IC50 inhibitory half maximal concentration, Ki equilibrium constant, LEV levetiracetam, MES maximal electroshock seizure test, PTZ subcutaneous pentylenetetrazole seizure test, SV2A synaptic vesicle protein 2A. a Reproduced from Fig. 1 of Klitgaard et al. [7], licensed under CC BY-NC-ND 4.0. b Reproduced from Table 31.2 of D’Souza et al. [70], with permission from John Wiley & Sons, Ltd. Panel C: Reproduced with small modifications from Fig. 1 of Feyissa [71], licensed under CC BY-NC 4.0CC BY-NC · PubMed Central
Fig. 3 Overview of BRV metabolism. BRV brivaracetam, CYP cytochrome P450. Reproduced from Fig. 1 of Moseley et al. [17], licensed under CC BY-NC-ND 4.0
Fig. 3 Overview of BRV metabolism. BRV brivaracetam, CYP cytochrome P450. Reproduced from Fig. 1 of Moseley et al. [17], licensed under CC BY-NC-ND 4.0CC BY-NC · PubMed Central
Fig. 4 Median percent reduction in POS frequency from baseline (a) and ≥ 50% responder rates (b). BRV brivaracetam, POS partial-onset seizure (focal-onset seizure). Reproduced from Fig.3a and 2B of Ben-Menachem et al. [31], licensed under CC BY-NC-ND 4.0
Fig. 4 Median percent reduction in POS frequency from baseline (a) and ≥ 50% responder rates (b). BRV brivaracetam, POS partial-onset seizure (focal-onset seizure). Reproduced from Fig.3a and 2B of Ben-Menachem et al. [31], licensed under CC BY-NC-ND 4.0CC BY-NC · PubMed Central
Fig. 5 Greater than 50% responder rates in patients treated with BRV, with or without previous LEV exposure (a), percent reduction over PBO in 28-day adjusted POS frequency during the treatment period according to reason for previous discontinuation of LEV (b), and ≥ 50% responder rates for POS frequency from baseline to the end of treatment period according to reason for previous discontinuation of LEV (c). p values are derived from a logistic regression model with effects for treatment, study, and log-transformed baseline focal seizure frequency as a continuous covariate. All p values are exploratory. BRV brivaracetam, LEV levetiracetam, PBO placebo, POS partial-onset seizure (focal-onset seizure). Panel A: Reproduced from Fig. 1A of Asadi-Pooya et al. [32], licensed under CC BY-NC-ND 4.0. Panel B and C: Reproduced from Fig. 4C and D of Klein et al. [30], licensed under CC BY-NC-ND 4.0
Fig. 5 Greater than 50% responder rates in patients treated with BRV, with or without previous LEV exposure (a), percent reduction over PBO in 28-day adjusted POS frequency during the treatment period according to reason for previous discontinuation of LEV (b), and ≥ 50% responder rates for POS frequency from baseline to the end of treatment period according to reason for previous discontinuation of LEV (c). p values are derived from a logistic regression model with effects for treatment, study, and log-transformed baseline focal seizure frequency as a continuous covariate. All p values are exploratory. BRV brivaracetam, LEV levetiracetam, PBO placebo, POS partial-onset seizure (focal-onset seizure). Panel A: Reproduced from Fig. 1A of Asadi-Pooya et al. [32], licensed under CC BY-NC-ND 4.0. Panel B and C: Reproduced from Fig. 4C and D of Klein et al. [30], licensed under CC BY-NC-ND 4.0CC BY-NC · PubMed Central
Fig. 6 Time to PPR elimination in patients with photosensitive epilepsy (a) and proportion of patients with PPR elimination on EEG at designated timepoints (b). Part 1: IV infusion over 15 min (n = 8); part 2: IV infusion over 15 min (n = 8); parts 1 and 2 combined (n = 16). aRange when excluding patient NNN (non-responder in Part 1): 1–5; bPatient OOO completed part 1, but patient PPP participated in part 2. BRV brivaracetam, EEG electroencephalogram, IV intravenous, LEV levetiracetam, PPR photoparoxysmal response. Adapted from Table 1 and 3 of Reed et al. [50], licensed under CC BY-NC 4.0
Fig. 6 Time to PPR elimination in patients with photosensitive epilepsy (a) and proportion of patients with PPR elimination on EEG at designated timepoints (b). Part 1: IV infusion over 15 min (n = 8); part 2: IV infusion over 15 min (n = 8); parts 1 and 2 combined (n = 16). aRange when excluding patient NNN (non-responder in Part 1): 1–5; bPatient OOO completed part 1, but patient PPP participated in part 2. BRV brivaracetam, EEG electroencephalogram, IV intravenous, LEV levetiracetam, PPR photoparoxysmal response. Adapted from Table 1 and 3 of Reed et al. [50], licensed under CC BY-NC 4.0CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 65 references

Research works printed but not linked: 2

  1. Mercier J, Holden D, Deo AK, et al. Brivaracetam achieves brain SV2A occupancy faster than levetiracetam. Epilepsy Curr. 2015;15(Suppl 1):343 (abstract 2.32).
  2. Steinhoff BJ, Christensen J, Doherty CP, et al. Cognitive performance and retention after 12-month adjunctive brivaracetam in difficult-to-treat patients with epilepsy in a real-life setting. Epilepsia. 2021;62:142–3 (abstract 96).

Cited by

See all 21

Metadata

Authors
Klein, P., & Bourikas, D.
Affiliations
Mid Atlantic Epilepsy and Sleep Center (US)
Corresponding author
Klein, Pavel
Venue
Advances in Therapy
Published
2024-05-29
Volume
41
Issue
7
Pages
2682-2699
ISSN
  • 0741-238X (ISSN-L)
  • 1865-8652
OpenAlex
W4399118098
Cited by
21
References
65
Citations by year
2026: 7 · 2025: 14
FWCI
1.67
Type
journal article
Language
en
Open access
Licence
Locations
  • Advances in Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
UCB Pharma
Topics
  • Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
  • Health Sciences › Medicine › Physiology (medical) › Diet and metabolism studies
Keywords
brivaracetam, epilepsy, antiepileptic drugs, SV2A, levetiracetam, focal seizures, adjunctive therapy, drug-resistant epilepsy, pharmacokinetics, drug-drug interactions, long-term tolerability, pediatric epilepsy, elderly patients, cognitive impairment, post-stroke epilepsy, brain tumor-related epilepsy
MeSH terms
Adult, Animals, Anticonvulsants, Child, Drug Evaluation, Preclinical, Epilepsy, Humans, Pyrrolidinones, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Narrative Review of Brivaracetam: Preclinical Profile and Clinical Benefits in the Treatment of Patients with Epilepsy. https://app.cochat.ai/papers/10.1007/s12325-024-02876-z
The paper
Klein, P., & Bourikas, D. (2024). Narrative Review of Brivaracetam: Preclinical Profile and Clinical Benefits in the Treatment of Patients with Epilepsy. Advances in Therapy. https://doi.org/10.1007/s12325-024-02876-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.